Bioassociate Announces Valuation Report on RedHill Biopharma, Ltd.
TEL AVIV, Israel, April 3, 2013
TEL AVIV, Israel, April 3, 2013 /PRNewswire/ --
Bioassociate has released valuation coverage on RedHill Biopharma, Ltd.
(NASDAQ: RDHL) (TASE:RDHL.TA). The Report contains a detailed discussion of
RedHill's business operations, market dynamics, macroeconomic data and
indicators, financial results, potential cash flows, and risks. The valuation
Report is available at:
Dr. Ofir Levi, Bioassociate's CEO: "RedHill is developing late clinical-stage,
improved and patented formulations of existing drugs. RedHill's most advanced
clinical program, RHB-103 - a fast dissolving thin film formulation of
rizatriptan for the treatment of migraine, submitted for FDA review by the end
of Q1 2013. RedHill's Pipeline is diverse and features six late stage clinical
programs that address multi-billion dollar markets. RedHill has an experienced
management team, Board of Directors and Advisory Board based in Israel, the
US, Canada and Europe, with successful track record at big and small
pharmaceutical companies. RedHill recently completed registration of its ADRs
on the Nasdaq Global Market.
We see great potential in RedHill's business platform and clinical development
programs. We anticipate deal making activities in the near future with
RedHill's advanced clinical programs. For these reasons we, at Bioassociate,
reached to a target price of $14.8 per share, which reflects an upside of 38%
over the current share price."
Bioassociate is an independent investment research firm specialized in the
life-science sector. Bioassociate helps inform readers about small-mid cap
life science companies without extensive analyst coverage. Bioassociate
structures its teams with multidisciplinary members to conduct specific
assignments. The Bioassociate team has industry experience as well as
consulting and research track record, providing investors with in-depth
scientific insights and their financial manifestation.
The research report described in this press release is not constructed as an
offer to sell or the solicitation of an offer to buy any security in any
jurisdiction where such an offer would be illegal. Bioassociate is not
soliciting any action based upon this material. It does not take into account
the particular investment objectives, financial situation, risk profile or
other needs of individual investors. Before acting on any advice or
recommendation in this material, an investor should consider whether it is
suitable for his/her particular circumstances and, if necessary, seek
professional advice. The report is based upon information that we consider
reliable, but we do not represent that it is accurate or complete, and it
should be relied upon as such. Opinions expressed are Bioassociate's current
opinions as of the date appearing on this material only; such opinions are
subject to change without notice. RedHilll is a client of Bioassociate and is
paying Bioassociate a cash fee for Bioassociate's services, which include the
preparation of equity research and valuation reports. The research report is
based on public information and on information provided by RedHill, which
according to RedHill is available publicly.
Please read each report's full disclosures and analyst background on
Bioassociate website, http://www.bioassociate.com, before investing.
Bioassociate is not a registered investment adviser or broker-dealer.
The research report described in this press release contains forward-looking
data subject to risks and uncertainties that could cause actual results to
differ materially from those projected. These forward-looking data represent
Bioassociate's judgment as of the date of this release. Bioassociate
disclaims, however, any intent or obligation to update this forward-looking
Press spacebar to pause and continue. Press esc to stop.